Reply:
Liang Peng, Zhi‐liang Gao – 10 October 2011
Reply:
Isabelle Colle, Christophe Van Steenkiste – 10 October 2011
Reply:
Chao‐Wei Hsu, Chau‐Ting Yeh – 4 October 2011
Hepatitis B virus mutants associated with hepatitis b surface antigen loss: Chicken or egg?
Tai‐Chung Tseng, Jia‐Horng Kao – 3 October 2011
Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis
Naim Alkhouri, Gaurav Kistangari, Carla Campbell, Rocio Lopez, Nizar N. Zein, Ariel E. Feldstein – 3 October 2011
Acute fulminant hepatitis with bone marrow failure in an adult due to parvovirus B19 infection
Li Sun, Jiu‐Cong Zhang – 3 October 2011
Poster sessions
30 September 2011
Author index
30 September 2011
Oral presentations
30 September 2011
Sirolimus‐based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta‐analysis
Wenhua Liang, Dongping Wang, Xiaoting Ling, Andrew Allen Kao, Yuan Kong, Yushu Shang, Zhiyong Guo, Xiaoshun He – 30 September 2011 – Sirolimus (SRL) is a novel immunosuppressant with antitumor properties. We performed a meta‐analysis to determine whether SRL can improve patient survival and decrease the risks of tumor recurrence in patients with a pretransplant diagnosis of hepatocellular carcinoma (HCC). We searched databases for controlled clinical trials assessing the survival and oncological benefits of SRL for liver transplant recipients with pretransplant HCC.